KB301

AXP000199.1 · Viral vector gene therapy

Platform
HSV-1 (replication-defective)
Targets
COL3A1
Originator
Jeune Aesthetics (Krystal Biotech)
Sponsor
Jeune Aesthetics (Krystal Biotech)

Names

NameTypeSource
KB301preferred name, codecurator, press
PEARL-1 ambiguoussynonympress

Virus

Role
In vivo gene transfer
Family
Herpesviridae
Virus
herpes simplex virus 1 (NCBI Taxonomy 10298)
Replication
non replicating
Modifications
replication-defective, non-integrating HSV-1 backbone; two copies of COL3A1
Transgenes
COL3A1
Route
intradermal
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT04540900A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin DepressionsActive not recruitingPhase 12020-10-072024-10-1685Fine Lines; Skin Roughness; Skin Thickness; Wrinkle

Recent changes

No changes recorded in its trials yet.

Notes

Intradermal replication-defective, non-integrating HSV-1 vector delivering two copies of COL3A1 to raise type III collagen in skin; phase 1 PEARL-1, NCT04540900, in aesthetic indications (lateral canthal lines, decollete wrinkles). Aesthetic rather than disease indication, but a human gene therapy in a registered trial, so in scope.

How to cite

KB301 (AXP000199.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000199.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.